What is Novartis without Sandoz? Vas Narasimhan is 'patient' as new company takes form

Nicole DeFeudis

Editor

Vas Narasimhan is steadfast on his mission to reshape Novartis, culling a few programs last quarter and making the final arrangements to spin off generics …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

What is Novartis without Sandoz? Vas Narasimhan is 'patient' as new company takes form

Nicole DeFeudis

Editor

Sign up to read this article for free.

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

BioMarin turns to ex-Roche dealmaker James Sabry to build ‘next version’ of 27-year-old company

Updated: Biogen makes cuts across its research unit, shifting focus to ‘external opportunities’

AbbVie partners with Neomorph in latest molecular glue deal

China's biotech boom is threatening US drugmakers' dominance

Samsung Bio hits revenue high, secures largest contract to date

Fueling More Breakthroughs: Manufacturing Innovation to Expand Gene Therapy’s Reach

What is No­var­tis with­out San­doz? Vas Narasimhan is 'pa­tien­t' as new com­pa­ny takes form

Editor

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

What is Novartis without Sandoz? Vas Narasimhan is 'patient' as new company takes form